Cargando…

Clinical factors predicting drug-induced liver injury due to flucloxacillin

OBJECTIVES: Drug-induced liver injury (DILI) is a serious adverse reaction due to flucloxacillin. The pathogenesis is not fully understood. Female sex, age over 60 years, and a longer treatment duration have been suggested to be predisposing factors. Carriers of HLA-B*57:01 have an 80-fold increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindh, Mikaela, Hallberg, Pär, Yue, Qun-Ying, Wadelius, Mia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254585/
https://www.ncbi.nlm.nih.gov/pubmed/30538582
http://dx.doi.org/10.2147/DHPS.S178394
_version_ 1783373748531888128
author Lindh, Mikaela
Hallberg, Pär
Yue, Qun-Ying
Wadelius, Mia
author_facet Lindh, Mikaela
Hallberg, Pär
Yue, Qun-Ying
Wadelius, Mia
author_sort Lindh, Mikaela
collection PubMed
description OBJECTIVES: Drug-induced liver injury (DILI) is a serious adverse reaction due to flucloxacillin. The pathogenesis is not fully understood. Female sex, age over 60 years, and a longer treatment duration have been suggested to be predisposing factors. Carriers of HLA-B*57:01 have an 80-fold increased risk, but due to the rarity of the reaction, testing of all patients is not cost-effective. We aimed to validate and detect clinical risk factors for flucloxacillin DILI. METHODS: Clinical characteristics of flucloxacillin-treated patients with (n=50) and without DILI (n=2,330) were compared in a retrospective case control study. Cases were recruited from the Swedish database of spontaneously reported adverse drug reactions. Treated controls were selected from the Swedish Twin Registry. Statistical comparisons were made using chi-squared test and logistic regression. The significance threshold was set to P<0.00357 to correct for multiple comparisons. Reliable variables were tested in a multiple regression model. RESULTS: DILI was associated with female sex, OR 2.79, 95% CI 1.50–5.17, P=0.0011, and with a history of kidney stones, OR 5.51, 95% CI 2.21–13.72, P=0.0003. Cases were younger than controls, OR per increase in years 0.91, 95% CI 0.88–0.94, P<0.0001, probably due to selection bias. No difference in treatment duration was detected, OR 1.03, 95% CI 0.98–1.08, P=0.1790. CONCLUSION: We established female sex as a risk factor for flucloxacillin-induced DILI, and a history of kidney stones was identified as a potential risk factor. Clinical risk factors for flucloxacillin-induced DILI could be used to indicate whom to test for HLA-B*57:01 before treatment.
format Online
Article
Text
id pubmed-6254585
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62545852018-12-11 Clinical factors predicting drug-induced liver injury due to flucloxacillin Lindh, Mikaela Hallberg, Pär Yue, Qun-Ying Wadelius, Mia Drug Healthc Patient Saf Original Research OBJECTIVES: Drug-induced liver injury (DILI) is a serious adverse reaction due to flucloxacillin. The pathogenesis is not fully understood. Female sex, age over 60 years, and a longer treatment duration have been suggested to be predisposing factors. Carriers of HLA-B*57:01 have an 80-fold increased risk, but due to the rarity of the reaction, testing of all patients is not cost-effective. We aimed to validate and detect clinical risk factors for flucloxacillin DILI. METHODS: Clinical characteristics of flucloxacillin-treated patients with (n=50) and without DILI (n=2,330) were compared in a retrospective case control study. Cases were recruited from the Swedish database of spontaneously reported adverse drug reactions. Treated controls were selected from the Swedish Twin Registry. Statistical comparisons were made using chi-squared test and logistic regression. The significance threshold was set to P<0.00357 to correct for multiple comparisons. Reliable variables were tested in a multiple regression model. RESULTS: DILI was associated with female sex, OR 2.79, 95% CI 1.50–5.17, P=0.0011, and with a history of kidney stones, OR 5.51, 95% CI 2.21–13.72, P=0.0003. Cases were younger than controls, OR per increase in years 0.91, 95% CI 0.88–0.94, P<0.0001, probably due to selection bias. No difference in treatment duration was detected, OR 1.03, 95% CI 0.98–1.08, P=0.1790. CONCLUSION: We established female sex as a risk factor for flucloxacillin-induced DILI, and a history of kidney stones was identified as a potential risk factor. Clinical risk factors for flucloxacillin-induced DILI could be used to indicate whom to test for HLA-B*57:01 before treatment. Dove Medical Press 2018-11-21 /pmc/articles/PMC6254585/ /pubmed/30538582 http://dx.doi.org/10.2147/DHPS.S178394 Text en © 2018 Lindh et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Lindh, Mikaela
Hallberg, Pär
Yue, Qun-Ying
Wadelius, Mia
Clinical factors predicting drug-induced liver injury due to flucloxacillin
title Clinical factors predicting drug-induced liver injury due to flucloxacillin
title_full Clinical factors predicting drug-induced liver injury due to flucloxacillin
title_fullStr Clinical factors predicting drug-induced liver injury due to flucloxacillin
title_full_unstemmed Clinical factors predicting drug-induced liver injury due to flucloxacillin
title_short Clinical factors predicting drug-induced liver injury due to flucloxacillin
title_sort clinical factors predicting drug-induced liver injury due to flucloxacillin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254585/
https://www.ncbi.nlm.nih.gov/pubmed/30538582
http://dx.doi.org/10.2147/DHPS.S178394
work_keys_str_mv AT lindhmikaela clinicalfactorspredictingdruginducedliverinjuryduetoflucloxacillin
AT hallbergpar clinicalfactorspredictingdruginducedliverinjuryduetoflucloxacillin
AT yuequnying clinicalfactorspredictingdruginducedliverinjuryduetoflucloxacillin
AT wadeliusmia clinicalfactorspredictingdruginducedliverinjuryduetoflucloxacillin